Our findings suggest that the disruption of HDAC2-SMAD3-SKI axis with the use of HDAC2-specific brain penetrant small molecule inhibitors, has potential as a promising and global therapeutic strategy for targeting the drug-resistant and self-renewing BTSC population in GBM. This evidence concerns the gene SKI and glioblastoma.